CONCORDBIO: Revenue and profit fell in FY26, but new launches and compliance set up strong FY27 growth

About this update from Concord Biotech Ltd.

FY26 revenue and profit declined due to procurement delays and global uncertainties, but regulatory compliance, new facility commercialization, and product launches position the business for strong growth in FY27. Management remains optimistic given a robust order pipeline.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Concord Biotech Ltd.